Efter markedsføring er der set tilfælde af anafylaktiske/ anafylaktoide reaktioner, inklusiv angioødem, adskillige timer efter den intravitreale administrationsprocedure med pegabtanib.
Cases of anaphylaxis/ anaphylactoid reactions, including angioedema, have been observed within several hours after the pegaptanib intravitreal administration procedure in the post-marketing experience.